Patrick F Rivard1, Andrea C Nugent, Frank J Symons. 1. Gillette Children's Specialty Healthcare, Neurodevelopment Pediatrics, University of Minnesota, Minneapolis, MN, USA. symon007@umn.edu
Abstract
OBJECTIVE: To test the hypothesis that pain would be reduced after botulinum toxin type A (Btx/A) treatment for children with cerebral palsy (CP). METHOD: Thirty-four pediatric patients with CP (mean age 9 y; 56% male) and their parents were recruited through a regional specialty healthcare center medical clinic and pain research program. A 1-group pretest, posttest treatment design was used on the basis of a standardized parent-proxy report of their child's pain. RESULTS: Overall parent ratings of their child's pain were significantly reduced after Btx/A injection with 62% of parents reporting the absence of pain 1 month after injection (proportion=0.38; 95% confidence interval=0.23-0.55). There were no significant differences for males or females. CONCLUSIONS: Although there is considerable evidence that Btx/A is efficacious for the treatment of spasticity associated with CP, there is little direct evidence specific to associated analgesic effects after Btx/A treatment. These preliminary findings indicate that Btx/A treatment for spasticity resulted in significant pain reduction for this patient sample. This was the first study to directly ask parents about their child's pain pre-Btx/A and post-Btx/A treatment. These findings have implications for the management of pain associated with spasticity and CP and suggest further research is warranted.
OBJECTIVE: To test the hypothesis that pain would be reduced after botulinum toxin type A (Btx/A) treatment for children with cerebral palsy (CP). METHOD: Thirty-four pediatric patients with CP (mean age 9 y; 56% male) and their parents were recruited through a regional specialty healthcare center medical clinic and pain research program. A 1-group pretest, posttest treatment design was used on the basis of a standardized parent-proxy report of their child's pain. RESULTS: Overall parent ratings of their child's pain were significantly reduced after Btx/A injection with 62% of parents reporting the absence of pain 1 month after injection (proportion=0.38; 95% confidence interval=0.23-0.55). There were no significant differences for males or females. CONCLUSIONS: Although there is considerable evidence that Btx/A is efficacious for the treatment of spasticity associated with CP, there is little direct evidence specific to associated analgesic effects after Btx/A treatment. These preliminary findings indicate that Btx/A treatment for spasticity resulted in significant pain reduction for this patient sample. This was the first study to directly ask parents about their child's pain pre-Btx/A and post-Btx/A treatment. These findings have implications for the management of pain associated with spasticity and CP and suggest further research is warranted.
Authors: Frank J Symons; Issam ElGhazi; Brian G Reilly; Chantel C Barney; Leah Hanson; Angela Panoskaltsis-Mortari; Ian M Armitage; George L Wilcox Journal: Pain Med Date: 2014-09-19 Impact factor: 3.750
Authors: Florian Heinen; Michaela Bonfert; Petr Kaňovský; A Sebastian Schroeder; Henry G Chambers; Edward Dabrowski; Thorin L Geister; Angelika Hanschmann; Michael Althaus; Marta Banach; Deborah Gaebler-Spira Journal: J Pediatr Rehabil Med Date: 2022
Authors: Chantel C Barney; Stacy M Stibb; Alyssa M Merbler; Rebekah L S Summers; Supreet Deshpande; Linda E Krach; Frank J Symons Journal: Pain Rep Date: 2018-07-17
Authors: Chantel C Barney; Alyssa M Merbler; Jean Stansbury; Linda E Krach; Michael Partington; Patrick Graupman; Peter D Kim; Debbie Song; Frank J Symons Journal: Arch Rehabil Res Clin Transl Date: 2020-03-09